Stocks to Watch: Penguin Solutions, Esperion Therapeutics

Dow Jones

Oct 08

By Kelly Cloonan

Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading.

Esperion Therapeutics commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

October 07, 2025 19:04 ET (23:04 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573994973"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573994973\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573994973?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 07:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573994973","market":"fut","top_or_hot":-1,"title":"Stocks to Watch: Penguin Solutions, Esperion Therapeutics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading. \n</p>\n<p>\n  Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 07, 2025 19:04 ET (23:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Penguin Solutions, Esperion Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Penguin Solutions, Esperion Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-08 07:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading. \n</p>\n<p>\n  Esperion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n   Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 07, 2025 19:04 ET (23:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2573994973","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573994973","pubTimestamp":1759878240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading.Esperion Therapeutics commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ESPR":"Esperion Therapeutics Inc."},"translate_title":"值得关注的股票：Penguin Solutions、Esperion Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESPR":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Penguin Solutions expects sales growth to slow in the current fiscal year after it swung to a profit in its latest quarter. The artificial intelligence company forecast sales growth of about 6%, plus or minus 10%, for fiscal 2026, compared to 17% growth in the year that ended Aug. 29. Chief Executive Mark Adams said the company is seeing momentum in its core businesses. Shares fell 13% to $23.60 in after-hours trading. \n\n\n  Esperion Therapeutics commenced an underwritten public offering of its common stock. All shares in the proposed offering will be sold by Esperion. In April, the biopharmaceutical company filed for a $400 million mixed shelf offering with the Securities and Exchange Commission. Shares slid 18% to $2.54 after market close. \n\n\n \n\n\n   Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  October 07, 2025 19:04 ET (23:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}